Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc. provides laboratory services spanning diagnostics and drug development laboratory capabilities for doctors, hospitals, pharmaceutical companies, researchers and patients. News about LH commonly covers earnings releases and guidance, dividend declarations, specialty and companion diagnostics, oncology testing, drug-screening products, and collaborations that expand access to advanced laboratory services.
Company updates also address Labcorp's Diagnostics Laboratories and Biopharma Laboratory Services activities, including FDA-cleared or FDA-approved tests, pediatric diagnostics development, real-world data platforms, digital pathology and AI-enabled laboratory operations. Recurring announcements connect Labcorp's national diagnostic infrastructure with health systems, biopharmaceutical customers and technology partners.
Labcorp (NYSE: LH) has announced a quarterly cash dividend declaration of $0.72 per share of common stock. The dividend will be paid on June 11, 2025, to stockholders of record at the close of business on May 29, 2025. The announcement comes from the company's Board of Directors, reinforcing their commitment to returning value to shareholders.
Labcorp (NYSE: LH) has launched a groundbreaking blood-based biomarker test nationwide to aid in Alzheimer's disease diagnosis. The pTau-217/Beta Amyloid 42 Ratio test offers results comparable to PET imaging and CSF testing, with 95% sensitivity and specificity.
This innovative immunoassay measures two distinct biomarkers: pTau-217 and Beta Amyloid 42 in ratio, meeting performance criteria to confirm amyloid pathology consistent with Alzheimer's. The test is available at physician offices and Labcorp's 2,000+ Patient Service Centers nationwide, offering a less invasive alternative to current diagnostic methods.
With 6.9 million Americans living with Alzheimer's and diagnosis typically taking 2.8 years from symptom onset, this breakthrough aims to accelerate the diagnostic process. The test is available for both clinical trials and patient care, with data presentation scheduled at the American Association of Neurology's 2025 Annual Meeting in San Diego.
Labcorp (NYSE: LH) announced nationwide rollout of FDA-approved self-collection solutions for HPV and STI testing, available from April 7, 2025. The service will be accessible at over 2,200 Patient Service Centers and participating physician offices across the US.
The initiative addresses critical healthcare gaps, as one in four women are not up-to-date with cervical cancer screenings. With over 13,000 women diagnosed with cervical cancer annually and approximately 4,000 deaths, this preventable disease remains a significant concern. The self-collection option includes testing for HPV and STIs (chlamydia, gonorrhea, trichomonas, and mycoplasma genitalium).
Key features include:
- Physician-ordered testing with private collection options
- Available at 2,200 Labcorp PSC locations
- Electronic results delivery to both physician and patient
- Follow-up with physician required for positive results
Labcorp (NYSE: LH) has announced it will release its first quarter 2025 financial results before market opening on Tuesday, April 29, 2025. The company will host a conference call and webcast at 9 a.m. ET on the same day to discuss the results.
Investors can access the earnings release and financial information on Labcorp's Investor Relations website. The webcast will be available in listen-only mode, with participants recommended to join 10 minutes before the start. A replay of the webcast will be accessible approximately two hours after the event concludes and remain available until April 16, 2026.
Labcorp (NYSE: LH) has announced an agreement to acquire select assets of BioReference Health's oncology and oncology-related clinical testing services from OPKO Health. The transaction, valued at up to $225 million, includes $192.5 million at closing and a potential $32.5 million performance-based earnout.
The acquired assets generate $85-100 million in annual revenue and will expand Labcorp's oncology diagnostic testing portfolio across the United States. The deal is expected to be earnings accretive in the first year and close in the second half of 2025.
Post-acquisition, BioReference Health will maintain its core clinical testing operations in the New York and New Jersey region, including its 4Kscore franchise, which generated approximately $300 million in revenue for 2024.
Labcorp (NYSE: LH) has announced the clinical availability of Labcorp® Plasma Complete™, a liquid biopsy test for comprehensive genomic profiling in patients with advanced solid tumors. The test analyzes circulating tumor DNA (ctDNA) from a simple blood draw, detecting genomic alterations across 521 genes, including various mutations, amplifications in 12 genes, and translocations associated with 12 genes.
The test features high sensitivity with variant detection as low as 0.1% and specificity exceeding 99.99%. It provides insights for FDA-approved therapies, guideline-driven treatments, and clinical trial eligibility. The solution has been validated in Labcorp's CAP-accredited and CLIA-certified laboratory, with validation studies published in the Journal of Molecular Diagnostics confirming its clinical accuracy.
Labcorp (LH) reported strong Q4 and full-year 2024 results, with Q4 revenue reaching $3.33 billion (up 9.8% YoY) and full-year revenue of $13.01 billion (up 7.0% YoY). The company's Q4 diluted EPS improved to $1.70 from $(1.95) last year, while adjusted EPS increased to $3.45 from $3.30.
Free cash flow showed significant improvement, with Q4 at $665.1 million (up from $412.4 million) and full-year at $1.10 billion (up from $748.7 million). The company completed 10 transactions in 2024 and launched new innovative tests in specialty areas.
For 2025, Labcorp projects revenue between $13.88-14.05 billion (7.4% growth at midpoint), adjusted EPS of $15.60-16.40 (9.8% growth at midpoint), and free cash flow of $1.10-1.25 billion (7.2% growth at midpoint).
Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company will engage in a fireside chat scheduled for Tuesday, January 14, at 3:45 p.m. Pacific Time.
Interested parties can access a live audio webcast of the discussion through Labcorp's Investor Relations website at ir.Labcorp.com. The session will also be archived for future viewing.
Labcorp (NYSE: LH) has announced a quarterly cash dividend of $0.72 per share of common stock. The dividend will be distributed on March 12, 2025, to stockholders recorded as of the close of business on February 27, 2025. This announcement comes from the global leader in innovative and comprehensive laboratory services, following a declaration by its Board of Directors.
Labcorp (NYSE: LH) has announced it will release its fourth quarter 2024 financial results before market opens on February 6, 2025. The company will host a conference call and webcast at 9 a.m. ET on the same day to discuss the results.
The earnings release and financial information will be available on Labcorp's Investor Relations website. Participants can join the listen-only webcast and conference call through registration, with recommended arrival 10 minutes before start time. A replay of the webcast will be accessible approximately two hours after the event and remain available until January 24, 2026.